The effect of intravitreal bevacizumab and ranibizumab on cutaneous tensile strength during wound healing

References

• ErinieriJPFongAJKemenyNEBrownKTGetraidmanGISolomonSBTiming of administration of bevacizumab chemotherapy affects wound healing after chest wall port placementCancer201111761296130121381016
   PubMedGoogle Scholar
• RosamondWFlegalKFurieKHeart disease and stroke statistic 2008 Update: a report from the American Heart Association Statistics Committee and Stroke Statistics SubcommitteeCirculation20081174e25e14618086926
   PubMed Web of Science ®Google Scholar
• RogersSMcIntoshRLCheungNfor the International Eye Disease ConsortiumThe prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and AustraliaOphthalmology20101172313319e120022117
   PubMed Web of Science ®Google Scholar
• YangJCHaworthLSherryRMA randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancerN Engl J Med2003359542743412890841
   PubMed Web of Science ®Google Scholar
• PouesselDCulineSHigh frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptorEur Urol200853237638117825982
   PubMed Web of Science ®Google Scholar
• AllegraCJYothersGO’ConnellMJInitial safety report of NSABP C-08: a randomized Phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancerJ Clinic Oncol2009272033853390
   PubMed Web of Science ®Google Scholar
• GordonCRRojavinYPatelMA review on bevacizumab and surgical wound healing: an important warning to all surgeonsAnn Plast Surg200962670770919461291
   PubMed Web of Science ®Google Scholar
• ZawackiWJWalkerTGDeVasherEWound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapyJ Vasc Interv Radiol200920562462719328717
   PubMed Web of Science ®Google Scholar
• ThorntonADRavnPWinsletMChesterKAngiogenesis inhibition with bevacizumab and the surgical management of colorectal cancerBr J Surg200693121456146317115389
   PubMed Web of Science ®Google Scholar
• ScappaticciFAFehrenbacherLCartwrightTSurgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumabJ Surg Oncol200591317318016118771
   PubMed Web of Science ®Google Scholar
• ChristoforidisJBRicketsRPrattCThe effect of intravitreal anti-VEGF agents on peripheral wound healing in a rabbit modelClin Ophthalmol20126616922275809
   PubMedGoogle Scholar
• ReidRRSaidHKMogfordJEMustoeTAThe future of wound healing: pursuing surgical models in transgenic and knockout miceJ Am College of Surgeons20041994578585
   Google Scholar
• GottrupFAgrenMSKarlsmarkTModels for use in wound healing research: a survey focusing on in vitro and in vivo adult soft tissueWound Repair Regen200082839610810034
   PubMed Web of Science ®Google Scholar
• BeckLSChenTLMikalauskiPAmmannAJRecombinant human transforming growth factor-beta 1 (rhTGF-beta 1) enhances healing and strength of granulation skin woundsGrowth Factors1990342672752257148
   PubMedGoogle Scholar
• GouldLJLeongMSonsteinJWilsonSOptimization and validation of an ischemic wound modelWound Repair Regen200513657658216283873
   PubMed Web of Science ®Google Scholar
• GuptaAJainGKRaghubirA time course study for the development of an immunocompromised wound model, using hydrocortisoneJ Pharm Toxicol Methods1999414183187
   Google Scholar
• MatsudaHKoyamaHSatoHRole of nerve growth factor in cutaneous wound healing: accelerating effects in normal and healing-impaired diabetic miceJ Exp Med199818732973069449710
   PubMedGoogle Scholar
• HowdieshellTRRiegnerCGuptaVCallawayDSathyanarayana McNeilPLNormoxic wound fluid contains high levels of vascular endothelial growth factorAnn Surg19982287077159833810
   PubMed Web of Science ®Google Scholar
• HuntTWound Healing and Wound Infection: theory and surgical practiceNew York, NYAppleton-Century-Crofts1980
   Google Scholar
• BrownLFVan De WaterLHarveryVSDvorakHFFibrinogen influx and accumulation of cross-linked fibrin in healing wounds and in tumor stromaAm J Pathol19881304554653279791
   PubMed Web of Science ®Google Scholar
• BreuingKErikssonELivPMillerDRHealing of partial thickness porcine skin wounds in a liquid environmentJ Surg Res19925250581548868
   PubMed Web of Science ®Google Scholar
• BoseDMeric-BernstamFHofstetterWReardonDAFlahertyKTEllisLMVascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient careLancet Oncol201011437338220171141
   PubMed Web of Science ®Google Scholar
• EllisLMCurleySAGrotheyASurgical resection after downsizing of colorectal liver metastasis in the era of bevacizumabJ Clinic Oncol20052348534855
   PubMed Web of Science ®Google Scholar
• SugrueMMPurdieDMFengSSerious wound healing complications (sWHC) following surgery in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV): results from the BRiTE observational cohort study (OCS)J Clin Oncol200826Suppl 15 abstr 4105
   Google Scholar
• HowdieshellTRCallawayDWebbWLAntibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formationJ Surg Res20019617318211266270
   PubMed Web of Science ®Google Scholar
• RichRMRosenfeldPJPulafitoCAShort-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degenerationRetina20062649551116770255
   PubMed Web of Science ®Google Scholar
• MichelsSRosenfeldPJPuliafitoCAMarcusENVenkatramanASSystemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical studyOphthalmology200511261035104715936441
   PubMed Web of Science ®Google Scholar
• MartinDFMaguireMGYingGSfor the CATT Research GroupRanibizumab and bevacizumab for neovascular age-related macular degenerationN Engl J Med2011364201897190821526923
   PubMed Web of Science ®Google Scholar
• CsakyKDoDVSafety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapiesAm J Ophthalmol2009148564765619712924
   PubMed Web of Science ®Google Scholar
• GaudreaultJWebbWVan HoyMPharmacokinetics and retinal distribution of AMD rhufab V2 after intravitreal administration in rabbitsAAPS Pharm Sci1999Suppl 13207
   Google Scholar
• ZhuQZiemssenFHenke-FahleSVitreous levels of bevacizumab and vascular endothelial growth factor-α in patients with choroidal neovascularizationOphthalmology20081151750175518708261
   PubMed Web of Science ®Google Scholar
• KrohneTUEterNHolzFGMeyerCHIntraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humansAm J Ophthlamol2008146508512
   PubMed Web of Science ®Google Scholar
• MauriceDMMishimaSPharmacology of the EyeNew YorkSpringer-Verlag1984
   Google Scholar
• DarlowBAEllsALGilbertCEGoleGAQuinnGEAre we there yet? Bevacizumab therapy for retinopathy of prematurityArch Dis Child Fetal Neonatal Ed Epub December 30, 2011
   Google Scholar
• MeyerCHKrohneTUHolzFGIntraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humansRetina2011311877188421738089
   PubMed Web of Science ®Google Scholar
• LinYSNguyenCMedozaJLPreclinical pharmacokinetics, interspecies scaling and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factorJ Pharmacol Exp Ther19992993713789862791
   PubMed Web of Science ®Google Scholar
• WatkinsRHD’AngioCTRyanRMPatelAManiscalcoWMDifferential expression of VEGF mRNA splice variants in newborn and adult hyperoxic lung injuryAm J Physiol Lung Cell Mol Physiol1999276858867
   PubMed Web of Science ®Google Scholar